Overview

Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

Status:
Terminated
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
In this proof-of-concept trial the investigators will study the effects of imatinib treatment on the biology of mesenchymal-type colon cancers.
Phase:
Phase 2
Details
Lead Sponsor:
UMC Utrecht
Collaborators:
Erasmus Medical Center
Hubrecht Institute
Meander Medical Center
Treatments:
Imatinib Mesylate